TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Scinai Immunotherapeutics ( (SCNI) ) just unveiled an update.
On December 2, 2025, Scinai Immunotherapeutics reported its financial results for the first nine months of 2025, highlighting significant growth in its CDMO business and advancements in its NanoAbs pipeline. The company saw a substantial increase in revenues compared to the previous year, driven by the expansion of Scinai Bioservices, including contributions from its U.S. subsidiary. Despite a net loss due to the absence of financial income from loan conversion recorded in 2024, Scinai continues to strengthen its position in the biotech industry. The company is advancing its NanoAbs pipeline with a focus on strategic partnerships and has received a non-dilutive grant from the Israel Innovation Authority to enhance its manufacturing capabilities. However, a recent grant application for the PC111 program was not approved, prompting Scinai to explore alternative funding options and strategic paths for the program.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that operates two main business units: Scinai Bioservices, a boutique CDMO offering analytical method development, process development, and clinical cGMP manufacturing services for biotech clients globally, and Scinai R&D, which focuses on developing innovative inflammation and immunology therapeutics using NanoAbs with unique physicochemical properties.
Average Trading Volume: 78,671
Technical Sentiment Signal: Sell
Current Market Cap: $853K
Learn more about SCNI stock on TipRanks’ Stock Analysis page.